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ABSTRACT 
Tocotrienols are fat soluble substances members of the vitamin E family with 
the main properties of antioxidant. They are composed of the chiral center of 
chromanol ring with polypreniyl side chains. Research suggests that tocotrienols 
have a number of health benefit, and one of them as an anticancer agent. As 
an anticancer, tocotrienols could perform in different processes of the multi 
stages of cancer development and interact with other anticancer medicines 
and other bioactive substances, suchs geneistein, lovastin, hydroxychavicol, 
6- gingerol and sesamin. The anticancer activities occur through their roles as 
antioxidant, coenzyme, gene expression regulator, and preventing cholesterol 
synthesis by inhibiting the expression of HMGCR enzyme after transcription, 
through this method, tocotrienols could control the cholesterol level of cancer 
cells and prevent the growth of the cancer. Tocotrienols target several signalling 
pathways at cellular and molecular levels.
ABSTRAK
Tocotrienol adalah zat larut lemak anggota keluarga vitamin E dengan sifat 
utama antioksidan. Zat tersebut terdiri dari pusat kiral cincin kromanol 
dengan rantai samping polypreniyl. Penelitian menunjukkan bahwa 
tokotrienol memiliki sejumlah manfaat kesehatan, dan salah satunya sebagai 
agen antikanker. Sebagai antikanker, tokotrienol dapat bekerja dalam proses 
yang berbeda dari berbagai tahap perkembangan kanker dan berinteraksi 
dengan obat antikanker dan zat bioaktif lainnya, seperti genistein, lovastin, 
hidroksikaviol, 6-gingerol, dan sesamin. Aktivitas antikanker terjadi melalui 
peran mereka sebagai antioksidan, koenzim, pengatur ekspresi gen, dan 
mencegah sintesis kolesterol dengan menghambat ekspresi enzim HMGCR 
setelah transkripsi, melalui metode ini, tocotrienol dapat mengontrol kadar 
kolesterol dari sel kanker dan mencegah pertumbuhan sel-sel kanker. Pada 
tingkat seluler dan molekuler, Tocotrienol menargetkan beberapa jalur 
pensinyalan pada tingkatan selular dan molekul.
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INTRODUCTION
Tocotrienol, one of vitamin E groups, 
is fat soluble antioxidant which are 
composed of chromanol core ring and 
polyprenyl side chain. Tocotrienol differs 
from other vitamin E groups such as 
tocopherol. Tocotrienols have polyprenyl 
side chains and have 3 unsaturated 
bonds at 3’, 7’ and 11’ positions which 
are connected to carbon number 2 of the 
chiral center (FIGURE. 1). This side chain 
gives non-polar properties to the whole 
molecule, and in the context of the cell, 
facilitates access of the fatty layer on 
the cell membrane.1 Like tocopherol, 
tocotrienol has four different isomers, 
based on the number and position of the 
methyl groups on the chromanol ring. 
They are α-tocotrienol 5,7,8-trimethyl; 
β-tocotrienol 5, 8-dimethyl; γ-tocotrienol 
7, 8-dimethyl and δ-tocotrien8ol 
8-monomethyl.2
FIGURE 1. Chemical Structure of Tocopherol and Tocotrienol 
adapted from Kasparek (1980).2
Tocotrienol was first reported by 
Bunyan (1961),3 when he wanted to 
know the biological properties of α and β 
tocopherol, which in fact found vitamin 
E with side chain was unsaturated, ie 
(2-methyl-2- (4 ‘, 8’, 12’-trimethyltrideca 
-3’, 7’, 11’-trienyl) chroman-6-ol. Then 
he gave a new name to the compound, 
namely ‘tocotrienol’. Bunyan also 
corrected vitamin E in wheat, known as 
Ɛ-tocopherol, whereas it is 5,8-dimetyl 
tocotrienol.. Research on tocotrienol 
continued with the discovery of the 
δ-tocotrienol isomer isolated from 
rubber latex,4 and started to receive 
attention in the early 1980s when it was 
first reported that tocotrienols were 
able to lower cholesterol levels in vitro 
in hepatocytes (liver parenchymal cells) 
chicken, mouse and in both experimental 
animals in vivo.5 In the early 1990s, the 
anti-cancer properties of tocotrienols 
were reported.6,7
Tocotrienols are exclusively 
synthesized only in photosynthetic 
organisms. The presence, distribution 
and concentrations of tocotrienols 
have been widely reported, primarily 
in palm oil, rice bran, wheat germ oil, 
coconut oil and annatto seeds. Palm oil 
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contains  0.66% α-tocotrienol, 0.019% 
β-tocotrienol, 0.71% γ-tocotrienol, 
0.31% δ-tocotrienol. Rice bran contains 
0.43% α-tocotrienol, 0.08% β-tocotrienol, 
0.63% γ-tocotrienol, 0.04% δ-tocotrienol. 
Wheat germ oil 1.94% α-tocotrienol and 
0.05% δ-tocotrienol, whereas in coconut 
oil there is 0.2% α-tocotrienol, 0.04% 
γ-tocotrienol, 0.76% δ-tocotrienol.8,9 In 
annatto seeds, most of the tocotrienol 
is δ-tocotrienol with a content ranging 
from 140-147 mg/100 g of dry seed.10 
The data above conclude that both the 
isomeric composition and the total 
content of tocotrienol vary greatly from 
one source to another. Palm oil, rice bran 
and annatto seeds are the main sources 
of tocotrienols.
Tocotrienols have a wide range 
of biological and health effects as a 
vitamin with antioxidant capacity. 
Tocotrienols exhibit an inhibitory effect 
of aging,11 cardioprotective effects,12,13 
anti-atherosclerosis,14 specifically protect 
the blood vessel wall in diabetics.15 
Tocotrienol also provides a protective 
effect on bone damage caused by ferric 
nitrilotriacetate free radicals in mouse 
model animals.16 The bone-protective 
effect is consistent with Norazlina’s 
findings that γ-tocotrienol intake in 
experimental animals fed with foods 
lacking of tocotrienols was capable of 
maintaining vitamin D metabolism 
under normal and homeostatic 
conditions of calcium. This effect was 
not happen to the experiment treated 
with α-tocopherol.17 Tocotrienol has 
also been reported as liver antitoxin18 
and gastroprotective, i.e preventing 
changes in acidity of the stomach due to 
the increase of gastrin.19 In combination 
with ascorbic acid, tocotrienol increases 
neutrophil and lymphocyte leukocytes 
that are part of the body’s defense 
system.20 It has also been tested for its 
ability to reduce joint inflammation in 
patients with rheumatoid arthritis.21 
Radioprotection of tocotrienols through 
its effect in apoptosis and increased 
hematopoesis after radiation have been 
reported by Satyamitra.22 The role of 
tocotrienol in cancer prevention and 
therapy is to inhibit the secretion of 
angiogenesis factors from cancer cells,22,23 
as adjuvant drugs to enhance anti-
cancer effectiveness through their role 
as immunomodulators.24,25 Tocotrienol, 
particularly the delta isomer, can be an 
alternative chemotherapy agents to treat 
lung cancer and brain cancer.26
Research on the interactive effects 
of natural ingredients with each other 
in relation to the biological and health 
functions of cancer patients, both in 
terms of prevention and treatment, 
is still an enormously questionable 
area, not to mention tocotrienols with 
other potential bioactive compounds. 
Therefore, the next section will 
examine the role of tocotrienols in 
cancer prevention and treatment, in 
inhibiting cancer cell growth, range of 
action and the synergistic interactions 
of tocotrienols and other bioactive 
substances, which were reported to have 
anticancer potential.
DISCUSSION
Tocotrienol as an anticancer
As well as many historical discoveries 
of nutrients and nutraceutical 
compounds, the discovery of the role of 
tocotrienols in cancer inhibition does 
not begin with a direct test of the effects 
of tocotrienols on inhibition of cancer 
cells, but through studies of the indirect 
effects of vegetable oils (palm oil and 
corn oil) to mice triggered by DMBA 
carcinogens (or 7,12-dimethylbenz [a] 
anthracene).27  Testing of palm oil rich 
in tocotrienol fractions (TRF, tocotrienol 
rich fraction) and α-tocopherol towards 
the proliferation of breast cancer cells 
of the positive MDA-MB-435, strains 
of estrogen receptor was the first 
experiment to prove that the tocotrienol 
fraction. It is responsible for inhibiting 
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proliferation cancer cells.28 Subsequent 
research proves that tocotrienol works as 
an anticancer in almost every important 
stage of cancer development.
By the nature of antioxidants, 
antiproliferative and pro-apoptotic, 
tocotrienol is considered capable of 
preventing the occurrence of cancer. 
However, whether the cellular signaling 
system influenced by tocotrienols has 
an antimutagenic effect has not been 
reported, but the role of tocotrienols and 
their application in ionizing radiation 
through several pathways, among 
others, DNA aberration protection,29 DNA 
damage reduction30 or by mobilization 
of progenitor cells,31 provides an 
opportunity for tocotrienol involvement 
as an antimutagen or ionizing radiation 
barrier that prevents the occurrence 
of genetic degeneration, which is a 
prerequisite for the emergence and 
development of cancer. This has been 
argued by Punvittayagul et al.32 for 
the antimutagenic effect of lipophilic 
extracts rich in tocotrienol from cv. 
Kum Doisaket purple rice husks from 
northern Thailand. 
At the promotional stage of cancer 
development, γ-tocotrienol was reported 
to inhibit cell proliferation and accelerate 
apoptosis of prostate cancer cells. The 
anti-proliferative effect of γ-tocotrienol 
acts via a NF-κB signaling pathway, 
in which γ-tocotrienol suppresses the 
activity of cancer prosurvival signal 
of NF-κB through the phosphorylation 
and accumulation I κBα/β (inhibitor of 
kappa B). In the same study reported 
that γ-tocotrienol induces apoptosis 
by activating pro-caspase. Caspase 
activation by γ-tocotrienol is associated 
with down-regulation of Id1, Id3 (Id 
of inhibitor of differentiation) and the 
EGF-R. ID1 and ID3 play a role in cell 
growth while EGF-R is involved in the 
development and progresion of cancer 
cells.33,34
Studies of the effects of γ-tocotrienols 
on breast cancer cells by Yap et al. showed 
that γ-tocotrienols induced apoptotic cell 
death as evidenced by the activation of 
procaspases, the accumulation of cells in 
G1 stages and DNA fragmentation.35 This 
death is related to suppression of the 
activity of the Id1 and the NF-kB genes. 
The role of γ-tocotrienols in this case is 
in modulating the upstream regulators 
of Id1 and NF-kB (ie, Src, SMAD 1/5/8, 
Fak, and LOX) . In the promotion stage, 
tocotrienol is also reported to suppress 
the activation of the receptor tyrosine 
kinases family genes (ErbB3, ErbB4, 
ErbB2 ErbB2) which are members of the 
epidermal growth factor receptor that 
are cancer-triggering genes.36
In the stage of cancer growth which 
occurs rapidly or is in the progression 
stage, combination treatment of the 
isomers of γ-tocotrienol and δ-tocotrienol 
was found effectively inhibiting the 
cells proliferation in HeLa cervical 
cancer through increased expression of 
proinflammatory central cytokines-6 (IL-
6) also back in turn decreases the cyclin 
expression of D3, p16, and CDK6 in the 
cell cycle signaling path.37 Both cyclin D3 
and p16 are suppressor activity of CDK6 
gene, which is a positive regulator of cell 
cycle.
A recent study demonstrates that the 
involvement of tocotrienols in cancer 
growth occurs through retardation of cell 
cycle progression in G1 phase coupled 
with apoptotic death, as demonstrated in 
bladder cancer cells. Interestingly, not all 
tocotrienol isomers give inhibitory and 
death effects. δ- and γ-tocotrienol have an 
anticancer effect, whereas α-tocotrienol 
has no effect. Furthermore, the role of 
cell cycle rate retardation occurs through 
increased levels of cell cycle inhibitor 
expression (p21, p27) and inhibition of 
cyclin D1 cell protein cycle expression. 
Induction of apoptosis through the 
expression of bax proapoptosis protein 
and vice versa emphasize the expression 
of antiapoptotic proteins Bcl-2, Bcl-xL, 
and Mcl-1.38
Tocotrienol is also reported to 
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inhibit the growth of malignant cells 
through induction of apoptosis in 
breast epithelial cells + neoplastic SA 
(Neoplastic + SA mammary epithelial 
cells).39 The induction of death occurs 
through the activation of caspase-8 
and caspase-3, a trajectory of apoptotic 
death mediated by receptors. However, 
it has been shown that tocotrienols in 
the apoptotic induction of cancer cells 
take place through both trajectories 
of death receptors; trajectory of 
mitochondrial stress (with trajectory of 
Bcl-2 antiapoptosis and procemesis of 
Bad and Bax) via caspase-9; trajectory 
of the endoplasmic reticulum with the 
involvement of PARP components or JNK 
components. Which pathway is affected, 
depends on the type of cancer cell.40
Intratumor vascularization 
(angiogenesis) is essential for rapid 
cancer growth and angiogenic growth 
factors produced by cancer cells play 
an important role.41,42 In this case, 
tocotrienol acts as an antiangiogenic 
factor.23,24 It is hypothesized that 
tocotrienols are involved in inhibition 
of tumor angiogenesis by the inhibitory 
expression of VEGF (vascular endothelial 
growth factor), HIF-1α (hypoxia-inducible 
factor-α), interleukin-8 (IL-8), and COX-2 
(cyclooxygenase 2). These factors play a 
critical role in cancer neovascularization 
. Using 2 cancer cell lines (ie DLD-1 and 
HepG2) Shibata et al.24 showed that 
at 2 μM concentrations, tocotrienols 
inhibited the hypoxic-induced VEGF 
secretion and IL-8 from the DLD-1 
cancer cell strain. Such inhibition occurs 
at the level of mRNA and protein by the 
δ-tocotrienol isomers. They even show 
that the mechanism of inhibition by 
these isomers by lowering the expression 
of HIF-1α protein or increasing its 
degradation. Interestingly, δ-tocotrienol 
does not affect the expression of COX-2 
mRNA induced by hypoxia but precisely 
at the level of its protein expression. 
Thus, tocotrienol inhibits the secretion 
of angiogenic factors from cancer cells.
Migration of cancer cells out of the 
initial tissue where cancer cells grow 
and develop is one of the critical phases 
in terms of clinical pathology of the 
cancer. At this stage, or the stage of cell 
migration and invasion, γ-tocotrienol 
is reportedly capable of inhibiting 
migration and invasion of the SGC-7901 
gastric adenocarcinoma cell strain, by 
acting to decrease the transcriptional 
activity of metalloproteinase matrices 
MMP-2 and MMP-9and by increasing 
the expression of tissue inhibitors of 
metalloproteinasesTIMP-1 and TIMP-2.43 
MMP-2 and MMP-9 are two important 
proteins that drivingcancer cells to be 
invasive and metastatic,44 while TIMPs 
are important to inhibit MMP activities.45 
Furthermore, in the process of invasion 
of prostate and melanoma cancer cells, 
γ-tocotrienol is reported to inhibit the 
invasion process by increasing the 
expression of E-chaderin and protein γ 
catenin. Treatment with γ-tocotrienol in 
PC-3 prostate cancer cells and G361 strain 
melanoma cancer cells decreased the 
expression of vimentin as mesenchymal 
markers, α-SMA (α-Smooth muscle 
actin), and twist transcription factor 
involved in regulating the development 
of mesenchymal epithelium.36,46
The development of cancer into 
metastatic stages begins with epithelial-
to-mesenchymal transisition (EMT) 
epithelial transition cells. In EMT, 
epithelial cells lose their cellular polarity 
and obtain mesensimal cell-cell mobility 
that allows them to invade surrounding 
tissue. The action of tocotrienols in 
cancer cells that end in anticarcinogenic 
properties can take place through a 
variety of cellular signaling types, 
namely (a) NF-kB-mediated pathways, 
(b) phophatidylinositol-2 kinase (PI3K) 
/ phosphoinositide-dependent / Akt, (c) 
the Raf / Erk track, and (d) the associated 
JNK path.47-50
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TABLE 1. Cancer drugs reported to be synergistic with tocotrienol
Type of medicine Type of cancer cell Isomer Mechanism
Tamoxifen Breast cancer cells α, γ and δ Inhibition of cancer cell 
proliferation 6
Erlotinib Breast cancer cells α and γ Inhibits  ErbB receptors37
Statins Various type of 
cancer cells
γ- and δ-isomers Suppression of 
proliferationthrougfh 
theinduction of G1 arrest 
and/or apoptosis51
Gemicitabine Pancreatic cancer 
cells




Inhibition of proliferation 
and  induction of apoptosis52
Celoxib Breast cancer cells γ-Tocotrienol Suppression of PGE2 levels 





Breast cancer cells γ-Tocotrienol Downregulation of COX-2, 
PGDS, and PGD2 synthesis
54
Synergistic interaction of tocotrienol 
and anti-cancer drugs
The survey proved that the 
combination of tocotrienol with anti-
tumor drug can produce significant 
synergistic response in inhibiting 
cancer. The reported types of medicine 
synergizes with tocotrienol in the 
inhibition of cancer growth can be seen 
in TABLE 1.
The interactive effects of tocotrienol 
with anti-cancer drugs such as tamoxifen 
show a particularly significant inhibition 
of the growth of estrogen receptor-
positive (MCF-7) breast cancer cells 
and estrogen receptor negative (MDA-
MB-435) breast cancer cells.6 Similarly, 
the combination of γ-tocotrienols with 
other anti-cancer drugs such as the 
tyrosine kinase inhibitor group (erlotinib 
or gefitinib) with the ErbB inhibitory 
receptor shows a more effective effect 
in reducing the growth of mamae 
tumor cells. Targeting ErbB receptors 
with combination therapy in mammary 
cancer patients with erlotinib dose (0.25 
μM) or gefitinib (0.5 μM) and γ-tocotrienol 
(0.5-3.0 μM) significantly inhibited 
the growth of mammary cancer.37 
Other cancer drugs such as statins also 
show synergies with a combination of 
γ-tocotrienol as an anti-cancer agent, as 
shown in the synergistic suppression of 
proliferation througfh the induction of 
G1 arrest and/or apoptosis.51 Another 
isomer δ-tocotrienol is reported to 
synergize with gemicitabine in inhibiting 
the growth of pancreatic cancer cells 
in vitro and in vivo by suppressing NF-
κB activity and the expression of target 
transcription by either inhibiting the 
proliferation or induction of apoptosis.52 
Furthermore, low doses of γ-tocotrienol 
in combination with celecoxib (selective 
COX-2 inhibitor) have been shown to be 
effective in suppressing breast cancer 
cell proliferation.53
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The interaction of tocotrienol with 
other bioactive compounds as an 
anticancer
Bioactive compounds are chemicas 
that have physiological and positive 
health effects. The role of the bioactive 
compound in the body is obtained 
when the compound reaches its site 
of action and by its presence and in 
its interaction with certain cellular 
components causes certain physiological 
effects as well. In this case, the effects of 
bioactive compounds are often studied 
as molecules that act independently 
with specific targets as well as their 
physiological effects. This perspective is 
certainly not wrong, but the physiological 
effects of bioactive compounds are 
often more critically evaluated in 
their interactive effects with other 
compounds. In this context, tocotrienol 
isomers have a great opportunity to 
work through their interactions with 
other bioactives, and this has been little 
reported, although still mechanically far 
from clarity. The next section deals with 
studies to demonstrate the interactions 
of tocotrienol with other biofuels that 
have links to anticancer effects.
The interaction of γ-tocotrienol with 
dietary polyphenols resveratrol and 
epigallocatechin gallate
The combination of γ-tocotrienols 
with resveratrol and epigallocatechin 
gallate (ECGG) were reported suppreses 
oncogene cyclin gene expression D1 
and bcl-2. It is functionally inhibit the 
proliferation of MCF-7 breast cancer 
cells through the induction of the plasma 
membrane redox enzyme NQO1.55
The synergistic interactions of 
γ-tocotrienol and sesamin
γ-Tocotrienol and a lipid soluble 
lignan extracted from sesame seed 
oil show anticancer activities with 
multiple-targets. Harikumar et al.56 see 
previous section for the tocotrienol. 
A question arise if the two compound 
work sinergistically or independently. 
First indication of synergistic interaction 
between the two was shown by 
the research that a diet containing 
sesame seed oil and tocotrienol rich 
fraction increases the consentration of 
tocotrienol in skin and adipose tissues of 
rat significantly.57 Considering the effect 
of sesamin on tocopherol catabolism,58 
and their catabolic pathway similarities 
with different kinetics, Parker et al. 
and Birringer et al.58,59 were sugested 
that the sesamin inhibit degradation of 
γ-tocotrienol in the tissues causing the 
accumulation of the γ-tocotrienol and 
its bioavailability. Akl et al.60 showed 
that the increase in bioavailability of 
γ-tocotrienol by the addition of sesamin 
enhances their sinergistic anticancer 
activity. Further studies to examine 
interactions of γ-tocotrienol and sesamin 
beyond its bioavailability, they found 
the two compounds show synergistic 
growth inhibition of mice +SA mammary 
cancer cell proliferation. They identified 
molecular components affected by the 
interactions betweenγ-tocotrienol and 
sesamin are the EGF-dependent pathway, 
since they sinergistically prevent the 
activation of ErbB receptor and its 
downstream signalling molecules. Other 
study by Akl et al.61 showed that in mouse 
and human mammary cancer cells, 
interaction effects between γ-tocotrienol 
and sesamin are through G1 cell cycle 
arrest by affecting cell cycle regulators 
of the G1/S phase transition.
The interaction of γ –tocotrienoland 
hydroxyl-chavicol
A major phenolic compound in Piper 
betle leaves, hydroxyl-chavicol (4-allyl-
catechol, 1-allyl-3.4-dihydroxybenzene) 
(EC), has been reported to possess anti-
carcinogenic properties by modulating 
different cellular signaling events.62 
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Combined studies of γ-tocotrienol 
and EC show synergies in inhibiting 
the proliferation of human glioma 
cells of strain 1321N1, SW1783, LN18, 
γ-tocotrienol combinations with doses of 
42-100 mg/mL and hydroxyl-chavicol 75 
-119 mg/mL increases apoptosis through 
the activation of caspase-3 signaling, 
in the cultured cell strain 1321N1 
the compound index (IC) is 0, 55 and 
SW1783 0.54. While in cell LN18 0,73. 
Thus the combination of γ-tocotrienol 
and hydroxyl-chavicol showed synergies 
in inhibiting cell proliferation through 
the induction of human glioma cell 
apoptosis.63
The interaction of γ-tocotrienol and 
6-gingerol
6-Gingerol (1-[4’-hydroxy-3’-
m e t h o x y p h e n y l ] - 5 - h y d r o x y - 3 -
decanone), a pungent ingredient of 
ginger (Zingiber officinale Roscoe) has 
been known to possess anticancer of 
various cancer types.64-67 Synergistic 
interactions between 6-gingerol and 
tocotrienol as anticancer were reported 
although still limited. It was proven 
that γ-tocotrienol and 6-gingerol when 
used in combination act synergistically 
increasing cytotoxicity and apoptosis 
in cancer cells. Yusof et al.68 found that 
the combination of γ-tocotrienol (0-150 
mg/mL) and 6-gingerol (0-300 mg/mL) 
for 24 hours showed significant anti-
proliferative and cytotoxicity effects, 
by increasing apoptosis of 21.2% in 
colorectal cancer cells of HT-29 and 55.4% 
in SW837. Further studies are needed to 
examine their mechanistic interactions 
as anticancer in various cancer cell types 
and in vivo.
The interaction of γ-tocotrienol and 
indole alkaloid, jerantinine
Jerantinines are related group of 
indole alkaloids from  leaf extract of 
the plant spesies of Tabernaemontana 
corymbosa. They consistes of 7 
molecules species (jerantine A-G) and 
most of them displayed pronounced 
in vitro cytotoxicity against human KB 
cells (IC50 <1 µg/mL).
69 A study reported 
that jerantinine A possess cytotoxic 
activity against vincristine-resistant 
nasopharyngeal carcinoma cells and it 
works through apoptosis and mitotic 
arrest.70 The other study have reported 
the effect of jelantinine B to inhibit 
human cancer cell lines. It significantly 
arrested cells at the G2/M. It also provoked 
significant increases in reactive oxygen 
species and apoptotic induction.71 
Interestingly that both jerantinine A and 
B has shown synergistic effects with 
tocotrienol as anticancer. Abubakar 
et al.72 demonstrated that low dose of 
jerantinine B in combination with lowe-
dose of  δ-tocotrienol induces a synergistic 
apoptosis in humanglioblastoma and 
colorectal adenocarcinoma cancer 
cells. Furthermore, a combination 
study between low dose of γ-tocotrienol 
(0-24 µg/mL) and fixed low dose of 
concentration of jerantinine A (IC20=0.16 
µg/mL), in order to reduce toxic effect 
on normal cells of the jerantonine A, 
induced a potent antiproliferative effect 
on U87MG cells and led to a reduction 
on the new half maximal inhibitory 
concentration of γ-tocotrienol (i.e. 
IC50=1.29µg/mL) as compared to that of 
individual γ-tocotrienol (i.e. IC50=3.17µg/
mL)
The interaction of tocotrienol and 
garcinol
One of tocotrienols’ action 
mechanisms in inhibiting cancer is 
through the NF-kB pathway, which 
is a transcription factor that serves 
to stimulate the expression of the 
regulated gene (NF-κB responsive genes). 
Tocotrienol suppresses the activity of 
iD1 and NF-κb.33-35 It is interesting that 
garcinol from the Garcinia indica plant 
is able to inhibit cancer by a similar 
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mechanism, suppressing the expression 
of I κBα and the antiapoptosis protein 
(Bcl-xL Bcl-2).73 NF-κВ is a transcription 
factor of anti-apoptotic genes such as 
Bcl-2 and Bcl-XL. It also regulates the 
antiproliferative Id member. The two 
bioactive compounds (garcinol and 
tocotrienol, especially γ-tocotrienol ) 
are also involved in STAT-3 signalling 
pathways as antiproliferative, pro-
apoptotic and chemosensitizing 
agents.74,75 Thus, if tocotrienol and 
garcinol show the inhibitory effect of 
antiapoptosis and antiproliferative on 
cancer cells through suppression of 
NF-κ activation, and STAT-3 signallig, 
combinatorial research between the two 
bioactive substances are interesting to 
further investigate.
Tocotrienol involvement in cancer 
control through inhibition of hmg-coa 
enzymes
Secondary metabolites in terpenoid 
groups (monoterpene, sesquiterpene, 
carotenoids and tocotrienols) are able 
to inhibit the synthesis of modestly 
cholesterol-and therefore lower LDL 
cholesterol.76 Tocotrienol rich fraction 
(200g) combined with corn oil (300g) 
was reported to reduce cholesterol 
levels by 15% of total serum cholesterol 
of 6.21-8.02 mM identified in humans 
hypercholesterol, while γ-tocotrienol 
(200g) cholesterol 31% of total 
serum cholesterol of 7.84 mM,77 then 
tocotrienols were reported to affect 
mevalonate pathways in mammalian 
cells by suppressing the expression of 
3-hydroxyl-3-methylglutaryl coenzyme 
A reductase (HMGCR) post-transcription, 
specifically modulate the mechanism 
intracellular by stimulating the 
degradation of HMGCR.78 The inhibitory 
activity is caused by terpenoid group 
compound which can inhibit the activity 
of HMGCR  post-transcription.
Inhibition of tocotrienols against 
HMGCR can be associated with 
mevalonate formation pathways resulting 
in a reduction in cellular substrate 
capability required for isoprenylation 
and as a final result is inhibition of the 
pro-carcinogenic pathway, so that the 
synthesis of mevalonate inhibited by 
the interaction of isoprenoids leads to a 
drastic reduction of two products in the 
tissues tumors: farnesyl pyrophosphate 
and geranylgeranyl pyrophosphate are 
important in growth control-associated 
proteins.
Tocotrienol, gene expression and 
cancer control
The fundamental question of 
tocotrienol’s role in a number of health 
problems, including its role as anticancer 
has not been clearly explained by its 
mechanism of action. However, number 
of studies provide evidence of tocotrienol 
involvement in these issues through 
the mechanism of gene expression. 
The involvement of tocotrienols in 
various levels of gene expression 
in transcriptional and translational 
mechanisms in the aging process of 
fibroblasts, mioblasts, suppression of 
HMG CoA reductase and radiation-
induced damage will be discussed more 
specifically to the mechanisms of gene 
expression and cancer control.
Tocotrienol is reportedly worked 
in the process of transcription to 
translation in the process of gene 
expression. Associated with gene 
expression, γ-tocotrienol is reported 
to prevent cellular aging in human 
diploid fibroblasts characterized by 
modulating cell cycle in the aging 
process by increasing the expression 
of genes encoding elastin and collagen 
fibrillers (ELN, COL1A) and decreasing 
the expression of cyclin D1 (CCND1), 
retinoblastoma RB1), metalloprotenase 
(MMP1) and interleukin (IL6).79 Research 
using microarray analysis, γ- tocotrienol 
was reported to increase the expression 
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of 100 differential genes, furthermore, 
using the NES (normalized enrichment 
score) analysis γ-tocotrienol was 
reported to modulate expression genes 
in extensive cellular functions such 
as inflammation, protein transport, 
apoptosis and homeostasis.80
At the post-transcription stage 
tocotrienol is reported to prevent the 
aging process of fibroblast diploid in 
humans via miRNAS modulation and 
target gene expression.81 Tocotrienol also 
regulates the production of cholesterol 
in mammalian cells through post 
transcription by suppressing HMG CoA 
reductase and specifically modulating 
intracellular mechanisms to control the 
degradation of protein reductase. Control 
of this enzyme activity has implications 
for the control of cholesterol synthesis 
and mevalonant line products.82
Tocotrienol is involved in the 
inhibition of aging of human fibroblast 
cells. Giving a TRF will reduces the 
activity of β-galactosidase. It is involved 
in the acceleration of cell cycle by 
reducing the amount in G0/GI phase and 
increasing the cell in phase S. The TRF is 
observed to restore telomere elongation 
and activity and reduce DNA damage.54
Tocotrienol is reportedly involved not 
only in the process of gene transcription 
but also involved in the translational 
process proved that δ-tocotrienol protects 
the bone marrow in mice and CD34+ in 
humans from radiation damage through 
activation of extracellular signal kinases 
related to rapamycin pathway signaling 
target in mammals. The increased target 
of rapamycin and 4EBP-1 downstream 
effect or phosphorylation of mammals 
were associated with the translation 
activity of the eIF4E mRNA regulator and 
the S6 ribosome protein responsible for 
growth and survival.
The involvement of tocotrienols in 
gene expression levels is not only limited 
to transcriptional and translational 
mechanisms but some studies have 
reported that tocotrienols act on the level 
of gene expression as a cancer control. 
Studies in animal model have shown that 
the excessive expression of PPARγ that 
plays a role in the transcription process 
is associated with increased growth of 
mammary tumors, whereas suppression 
of PPARγ expression significantly inhibits 
the development of mammary tumors. 
Therefore, PPARγ can be an effective 
means of inhibiting expression of breast 
cancer growth by modifying tocotrienols 
that have anticancer effects. Malaviya & 
Sylvester54 confirmed that the combined 
treatment of γ-tocotrienol with PPARγ 
synergizes agonistically in inhibiting 
cell growth of MCF- 7 and MDA-MB-231. 
These findings suggest that excessive 
PPARγ expression correlates with breast 
enhancement, growth and viability of the 
breast and treatment with γ-tocotrienol 
is a significant treatment in decreasing 
PPAR expression. The combination of 
γ-tocotrienols each with epigallocatechin 
gallate (EGCG) and resveratrol in the 
MCF-7 breast cancer cell strain showed 
significant effects in reducing expression 
of Bcl-2 and cyclin D1, subsequently 
reported that α- γ-tocotrienol may 
increase catalase activity in strains cell 
MCF-7 and α-, δ- tocotrienol can increase 
the activity of glutathione peroxidase 
in MDA-MB-231 cell strain, tocotrienol 
isomer inhibits cancer by altering NRF2/
KEAPI transcription control which is a 
mediator of oxidative stress response 
regulating genes of more than 100 
antioxidants.83
CONCLUSION
Tocotrienol is one of vitamin E 
groups with the main property is fat 
soluble antioxidants and plays an 
important role as antioxidants and free 
radical control. One of the prominent 
roles of tocotrienol is as an anti-cancer 
agent, which is involved in various 
stages of cancer progress from initiation 
stage to invasion and metastasis stage. 
Tocotrienol works through various cell 
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signaling systems and causes slowing 
of cell cycle progress, suppressing cell 
cycle rate, apoptotic death, maintaining 
and/or restoring genome integrity. 
This bioactive synergizes with other 
bioactive substances  with a wide range 
of chemicals, including hydrochavicol, 
farnesol, genisten, pomegranate extract 
and with some anticancer drugs (a.l. 
gemicitabine and erlotinib). The 
anticancer properties of tocotrienols 
are also involved through inhibition 
of cholesterol synthesis, one of which 
suppresses activation of HMG-CoA 
enzymes in cancer cells. The key lies in 
the fact that cancer cells in their growth 
require large amounts of cholesterol. The 
need for a mechanistic explanation of how 
tocotrienols, with their divergent effects 
foreach isomers and in combination, 
acts as an anticancer througha wide 
range mode of actions. This provides 
an advanced research space to bring 
about a more thorough understanding 
in order to develop an anticancer system 
that involves more specific and effective 
bioactive compounds.
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